The looming storm: blood and cytokines in COVID-19

S Kaur, R Bansal, S Kollimuttathuillam, AM Gowda… - Blood reviews, 2021 - Elsevier
A novel coronavirus termed as COVID-19 by WHO has been the causative agent of an
unprecedented pandemic in the history of humanity. The global burden of mortality and …

The overall impact of COVID‐19 on healthcare during the pandemic: a multidisciplinary point of view

N Sabetkish, A Rahmani - Health Science Reports, 2021 - Wiley Online Library
Abstract Background and Aims The Coronavirus disease 2019 (COVID‐19) pandemic
globally changed the priorities of medical and surgical procedures. It has caused many …

[HTML][HTML] Coronavirus disease among persons with sickle cell disease, United States, March 20–May 21, 2020

JA Panepinto, A Brandow, L Mucalo… - Emerging Infectious …, 2020 - ncbi.nlm.nih.gov
Sickle cell disease (SCD) disproportionately affects Black or African American persons in the
United States and can cause multisystem organ damage and reduced lifespan. Among 178 …

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection

CP Minniti, AU Zaidi, M Nouraie, D Manwani… - Blood …, 2021 - ashpublications.org
We aimed to identify predictors of outcomes and survival in patients living in 4 major
metropolitan areas who had sickle cell disease (SCD) and COVID-19 to inform best …

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

WS Hoogenboom, TT Alamuri, DM McMahon… - Blood reviews, 2022 - Elsevier
Individuals with sickle cell disease (SCD) and sickle cell trait (SCT) have many risk factors
that could make them more susceptible to COVID-19 critical illness and death compared to …

Indications for transfusion in the management of sickle cell disease

H Han, L Hensch, VN Tubman - Hematology, 2021 - ashpublications.org
The transfusion of red blood cells (RBCs) is a crucial treatment for sickle cell disease (SCD).
While often beneficial, the frequent use of transfusions is associated with numerous …

[HTML][HTML] Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome

MH Odièvre, C de Marcellus, HD Le Pointe… - American journal of …, 2020 - ncbi.nlm.nih.gov
1. Thomas-Ruddel D, Winning J, Dickmann P, et al. Coronavirus disease 2019 (COVID-19):
update for anesthesiologists and intensivists March 2020. Anaesthesist. 2020; 69 (4): 225 …

COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes

JX Lee, WK Chieng, SCD Lau, CE Tan - Frontiers in Medicine, 2021 - frontiersin.org
This systematic review aimed to provide an overview of the clinical profile and outcome of
COVID-19 infection in patients with hemoglobinopathy. The rate of COVID-19 mortality and …

The wide spectrum of COVID-19 clinical presentation in children

N Nathan, B Prevost, C Sileo, N Richard… - Journal of clinical …, 2020 - mdpi.com
Background: Ten months after its appearance in December 2019, SARS-CoV-2 has infected
more than 25 million patients worldwide. Because children were first identified as potential …

[HTML][HTML] Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit

C Heilbronner, L Berteloot, P Tremolieres… - British Journal of …, 2020 - ncbi.nlm.nih.gov
Results From 1 March to 15 April 2020, 12 children with SCD were included, aged 5–17.5
years. RT‐PCR for SARS‐CoV‐2 was performed in 11of the 12 children and was positive in …